Heterogeneous Myocardial FDG Uptake and the Disease Activity in Cardiac Sarcoidosis

Tahara, Nobuhiro; Tahara, Atsuko; Nitta, Yoshikazu; Kodama, Norihiro; Mizoguchi, Masahiro; Kaida, Hayato; Baba, Kenkichi; Ishibashi, Masatoshi; Hayabuchi, Naofumi; Narula, Jagat; Imaizumi, Tsutomu

doi:10.1016/j.jcmg.2010.09.015

Cited by 151 publications

(88 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…SUVs are defined as the radioactivity concentration in the region of interest in BqÁmL -1 /(injected dose in BqÁpatient weight in g -1 ). 55 Various metrics for quantification of FDG uptake in cardiac sarcoidosis have been reported, including the maximal SUV values in the heart (SUV max ), 45,55 the total SUV value of the heart, 55 mean SUV of the heart, 56 heart-to-blood pool SUV ratios, 57 coefficient of variance of SUVs, 58 and the volume, 59 and volume-activity 44,59 of voxels with intensities of FDG SUVs above various thresholds. While these methods have not been rigorously compared head-to-head, there is data to suggest that they perform better than visual assessment of normalized images to assess treatment response.…”

Section: F-fluorodeoxyglucose Positron Emission Tomographymentioning

confidence: 99%

A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology

Slart

Glaudemans

Lancellotti³

et al. 2018

Journal of Nuclear Cardiology

116

View full text Add to dashboard Cite

Section: F-fluorodeoxyglucose Positron Emission Tomographymentioning

confidence: 99%

A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology

Slart

Glaudemans

Lancellotti³

et al. 2018

Journal of Nuclear Cardiology

116

View full text Add to dashboard Cite

“…Radionuclide scintigraphy using thallium 201, gallium 67, or technetium 99m has shown a wide range of sensitivity, from 18% to 64%, with data suggesting that technetium is the most accurate agent. 6,8,22 Positron emission tomography (PET) scanning is more reliable, with sensitivities between 82% and 100%. However, the reported specificity for PET varies widely, between 39% and 91%.…”

Section: Discussionmentioning

confidence: 99%

Primary Cardiac Sarcoidosis with Syncope and Refractory Atrial Arrhythmia: A Case Report and Review of the Literature

Thangam

Nathan²,

Kar³

et al. 2016

Texas Heart Institute Journal

View full text Add to dashboard Cite

We discuss the case of a 38-year-old 3 Sarcoidosis is most often associated with the lungs, but the disease can manifest itself in any tissue. Cardiac involvement was not described until 1929. 4,5 In recent times, cardiac manifestations have been understood to play a greater role in sarcoidosis morbidity than previously thought. In this report, we present a case of primary cardiac sarcoidosis that was successfully treated with a hybrid pharmacologic, surgical, and catheterbased intervention. Case ReportA 38-year-old black man presented at our clinic for evaluation of his first syncopal episode and atrial fibrillation (AF), this last accompanied by a rapid ventricular rate that was refractory to diltiazem, metoprolol, and digoxin therapy. The patient reported shortness of breath, intermittent palpitations, and chest pain. His medical history was significant for hypertension, obstructive sleep apnea, and diabetes mellitus type 2. Further, he had an implantable cardioverter-defibrillator to prevent sudden cardiac death due to his congestive heart failure (left ventricular ejection fraction [LVEF], 0.20-0.25, at the time of implantation). No electrocardiogram before the onset of AF was available at the time of his presentation to our clinic.The patient's initial evaluation included a transesophageal echocardiogram (TEE) that suggested left atrial thrombus with a preserved LVEF of 0.50 to 0.55. Rigorous anticoagulation therapy with a target international normalized ratio (INR) of 3.0 maintained for 6 months was apparently unsuccessful in dissolving the atrial thrombus. The patient had a high risk for thrombus embolization and for further clot formation from his newly documented atrial flutter. We determined that he would benefit from a hybrid procedure incorporating surgical excision of the atrial appendage and atrial mass, with subsequent catheter-based ablation targeting the atypical flutter. The atrial flutter and AF were the only arrhythmias identified by means of rhythm monitoring.

show abstract

“…Takeda show diffusely increased myocardial FDG uptake (7,34). A recent study performed by Yokoyama et al nicely showed that FDG PET/CT with quantification of myocardial SUVmax provides a high sensitivity and specificity for diagnosing CS (16).…”

Section: Patient Monitoring Using Fdg Petmentioning

confidence: 99%

Clinical Application of <sup>18</sup>F-fluorodeoxyglucose PET and LGE CMR in Cardiac Sarcoidosis

Ohira

Yoshinaga

Manabe

et al. 2017

Annals of Nuclear Cardiology

View full text Add to dashboard Cite

Sarcoidosis is a multisystem granulomatous disease of unknown etiology that is characterized by the formation of non-caseating granulomas at various sites in the body. Cardiac sarcoidosis (CS) has been underdiagnosed in the past due to a lack of imaging modalities with high sensitivity. CS may cause various symptoms including conduction disturbance, ventricular arrhythmias, cardiac dysfunction and sudden cardiac death, which account for an increased mortality rate in these patients.

show abstract

Heterogeneous Myocardial FDG Uptake and the Disease Activity in Cardiac Sarcoidosis

Abstract: Heterogeneous myocardial FDG uptake may be a useful diagnostic marker of disease activity for CS.

Cited by 151 publications

References 19 publications

A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology

A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology

Primary Cardiac Sarcoidosis with Syncope and Refractory Atrial Arrhythmia: A Case Report and Review of the Literature

Clinical Application of <sup>18</sup>F-fluorodeoxyglucose PET and LGE CMR in Cardiac Sarcoidosis

Contact Info

Product

Resources

About